Lesia K. Dropulic, M.D.

Richard L. Wu, M.D.

Clinical Trials Program

NIH Main Campus, Bethesda, MD

Richard L. Wu, M.D. (He/Him/His)

Staff Clinician

Contact: For contact information, search the NIH Enterprise Directory.

Specialty(s): Allergy and Immunology, Internal Medicine
Provides direct clinical care to patients at NIH Clinical Center

Portrait of Richard L. Wu, M.D.

Major Areas of Research

  • Vaccinology
  • Allergy
  • Immunology
  • Infectious Diseases

Program Description

Richard Wu M.D. is a Principal Investigator and Medical Officer of multiple phase 1 clinical trials for vaccine candidates and monoclonal antibodies against infectious targets such as malaria, Ebola, COVID-19, HIV, influenza, and Nipah virus. He is responsible for designing, implementing, and providing oversight for clinical trials at the Vaccine Research Center. Additionally, he represents the Vaccine Research Center on collaborations with external academic and industry partners.

Biography

Education

M.D., Uniformed Services University, Bethesda, MD

B.S., B.A., University of California, Berkeley

Richard Wu M.D. is a clinical trials investigator at the Vaccine Research Center, and a medical officer for the United States Public Health Service. He completed his Internal Medicine residency at the Walter Reed National Military Medical Center and his Allergy/ Immunology fellowship at the National Institute of Allergy and Infectious Diseases. He is board certified in Internal Medicine and Allergy / Immunology. His research has been published in journals such as The New England Journal of Medicine, Nature Medicine and The Journal of Allergy and Clinical Immunology.

Clinical Studies

VRC 614: A Phase 1, Dose Escalation, Open-Label Clinical Trial With Experimental Controlled Human Malaria Infections (CHMI) to Evaluate Safety and Protective Efficacy of an Anti-Malaria Human Monoclonal Antibody, VRC-MALMAB0114-00-AB (L9LS), in Healthy Malaria-Naive Adults: NCT05019729

VRC 612: A Phase 1, Dose Escalation, Open-Label Clinical Trial With Experimental Controlled Human Malaria Infections (CHMI) to Evaluate Safety and Protective Efficacy of an Anti-Malaria Human Monoclonal Antibody, VRC-MALMAB0100-00-AB (CIS43LS), in Healthy, Malaria-Naive Adults: NCT04206332

VRC 325: A Phase I Open-Label Clinical Trial to Evaluate the Dose, Safety, Tolerability and Immunogenicity of Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV, In Healthy Adults: NCT04896086

Selected Publications

Park HJ, Brooks DI, Chavarria CS, Wu RL, Mikita CP, Beakes DE. Combining Discordant Serum IgE and Skin Testing Improves Diagnostic and Therapeutic Accuracy for Hymenoptera Venom Hypersensitivity Immunotherapy. J Allergy Clin Immunol Pract. 2022 Mar;10(3):837-843.e3.

Wu R, DiLorenzo A, Lotke M, Habeshian K, Brooks J, Keller MD, Kirkorian AY. Evaluation and Treatment of Febrile Ulceronecrotic Mucha-Habermann Disease With Ruxolitinib and Tocilizumab as Guided by Cytokine Profile. JAMA Dermatol. 2021 Nov 1;157(11):1381-1383.

Gaudinski MR, Berkowitz NM, Idris AH, Coates EE, Holman LA, Mendoza F, Gordon IJ, Plummer SH, Trofymenko O, Hu Z, Campos Chagas A, O'Connell S, Basappa M, Douek N, Narpala SR, Barry CR, Widge AT, Hicks R, Awan SF, Wu RL, Hickman S, Wycuff D, Stein JA, Case C, Evans BP, Carlton K, Gall JG, Vazquez S, Flach B, Chen GL, Francica JR, Flynn BJ, Kisalu NK, Capparelli EV, McDermott A, Mascola JR, Ledgerwood JE, Seder RA; VRC 612 Study Team. A Monoclonal Antibody for Malaria Preventionv. N Engl J Med. 2021 Aug 26;385(9):803-814.

Wu R, Lyons JJ. Hereditary Alpha-Tryptasemia: a Commonly Inherited Modifier of Anaphylaxis. Curr Allergy Asthma Rep. 2021 May 10;21(5):33.

Visit PubMed for a complete publication listing.

Content last reviewed on